Stevens–Johnson syndrome after treatment with STI571: a case report

• Liang‐Tsai Hsiao

• Hung‐Ming Chung

• Jen‐Tsun Lin

• Tzeon‐Jye Chiou

• Jin‐Hwang Liu

• Frank S. Fan

• Wei‐Shu Wang

• Chueh‐Chuan Yen

• Po‐Min Chen

抄録

Summary.  Between seven and 21% of patients treated with the specific tyrosine kinase inhibitor STI571 have been reported to develop mild‐to‐moderate severity of adverse cutaneous reactions. We report a patient in the blast crisis phase of chronic myeloid leukaemia who developed a life‐threatening cutaneous reaction, Stevens–Johnson syndrome, following 1 week of STI571 therapy. This report may serve to remind the clinician about the possible severe cutaneous side‐effects of STI571 before instituting more extensive clinical application of this agent in the future.

収録刊行物

• British Journal of Haematology

  British Journal of Haematology 117 (3), 620-622, 2002-05-19

  Wiley

キーワード

• Hematology

詳細情報

• CRID: 1363388844952934784
• NII論文ID: 30014738789
• DOI: 10.1046/j.1365-2141.2002.03499.x
• ISSN: 13652141
• ISSN: 00071048
• Web Site: https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2141.2002.03499.x
• Web Site: https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2141.2002.03499.x
• データソース種別:
  • Crossref
  • CiNii Articles